6 completed. 6 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 3 | 1 | Completed 1 |
Follow Paresthesia: new trials by email Literature Review of Paresthesia trials Research Report on Paresthesia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Using Intranasal Midazolam (INM) and Lidocaine for Uncooperative Children Midazolam, Lidocaine-Midazolam, Placebo - Burning Nose | Phase 2 / Phase 3 | Completed | Latakia University | 63 | 2017-06-01 | 2018-11-05 |
| ST266 in UV-induced Inflammation ST266 immediate, ST266 delayed - Skin Burns | Phase 2 | Completed | Noveome Biotherapeutics, formerly Stemnion | 10 | 2015-03-01 | 2019-05-15 |
| Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome. incobotulinumtoxinA, Placebo - Restless Leg Syndrome | Phase 2 | Completed | Yale University | 24 | 2012-09-01 | 2016-03-21 |
| Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy Low Dose: 16 mg Engensis (VM202), High Dose: 32 mg Engensis (VM202), Control- Placebo (normal saline) - Painful Diabetic Neuropathies | Phase 2 | Completed | Helixmith Co., Ltd. | 104 | 2012-08-01 | 2025-10-06 |
| Safety and Efficacy of PP4001 for the Treatment of Symptoms Associated With Uncomplicated Urinary Tract Infection PP4001, Placebo - Urinary Tract Infection | Phase 2 | Completed | Pinnacle Pharmaceuticals, Inc. | 261 | 2011-07-01 | 2011-10-19 |
| Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy Fluoride varnish, Oral Hygiene, CPP-ACP - Mucositis, Dry Mouth | Phase 2 | Completed | Azad University of Medical Sciences | 30 | 2011-03-01 | 2012-11-29 |
Diabetic Neuropathies (1) · Dysuria (1) · Hypesthesia (1) · Infections (1) · Mucositis (1) · Neuralgia (1) · Pain (1) · Restless Legs Syndrome (1) · Urinary Tract Infections (1) · Xerostomia (1)
Nervous System Diseases (6) · Neurologic Manifestations (6) · Pathological Conditions, Signs and Symptoms (6) · Sensation Disorders (6) · Signs and Symptoms (6) · Somatosensory Disorders (6) · Diabetes Complications (1) · Diabetes Mellitus (1) · Digestive System Diseases (1) · Dyssomnias (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastroenteritis (1) · Gastrointestinal Diseases (1)
Genetic Therapy (1) · Midazolam (1) · Oral Hygiene (1) · Saline Solution (1) · Toothbrushing (1) · casein phosphopeptide-amorphous calcium phosphate nanocomplex (1) · incobotulinumtoxinA (1)
Azad University of Medical Sciences (1) · Helixmith Co., Ltd. (1) · Latakia University (1) · Noveome Biotherapeutics, formerly Stemnion (1) · Pinnacle Pharmaceuticals, Inc. (1) · Yale University (1)
United States (3) · Iran (1) · South Korea (1) · Syria (1)
Bahman Jabbari, MD (1) · David L Steed, MD (1) · Elma D Baron, MD (1) · Jack Kessler, MD (1) · Nabih Raslan, Dr. (1) · Sepideh Banava, Assist-Prof (1) · Suma Krishnan (1) · Walaa Khalil, Dr. (1)